Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Aug;14(2):273–277. doi: 10.1111/j.1365-2125.1982.tb01973.x

Predictive indices for chlorpromazine therapy in schizophrenics.

P A Dixon, E Oforah, R Makanjuola
PMCID: PMC1427744  PMID: 7104178

Abstract

1 Response to chlorpromazine therapy was studied in 24 schizophrenics and 75% reduction in Brief Psychiatric Rating scale (BPRS) within 4 weeks of treatment was taken to indicate good response. 2 Test oral dose of CPZ (200 mg) was administered and serial blood samples and total urine excreted in 6 h were taken for analyses of CPZ and its metabolites. 3 Area under the plasma time curve (AUC) showed an inverted U-shaped relationship with % reduction in BPRS. 4 Three groups of patients were identified, responders, l- and h-group non-responders. 5 l- and h-groups respond on further treatment with haloperidol (30 mg daily) and ECT respectively. 6 Responders showed threshold metabolic molar fraction MMFHO-CPZ greater than or equal to 3.0 x 10(-5) and MMFHO-CPZ/MMFCPZ-SO greater than 1.

Full text

PDF
273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelsson S., Jönsson S., Nordgren L. Cerebrospinal fluid levels of chlorpromazine and it metabolites in schizophrenia. Arch Psychiatr Nervenkr (1970) 1975 Dec 31;221(2):167–170. doi: 10.1007/BF00431052. [DOI] [PubMed] [Google Scholar]
  2. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978 Feb;135(2):165–173. doi: 10.1176/ajp.135.2.165. [DOI] [PubMed] [Google Scholar]
  3. Curry S. H., Marshall J. H., Davis J. M., Janowsky D. S. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry. 1970 Apr;22(4):289–296. doi: 10.1001/archpsyc.1970.01740280001001. [DOI] [PubMed] [Google Scholar]
  4. Horn A. S., Snyder S. H. Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Natl Acad Sci U S A. 1971 Oct;68(10):2325–2328. doi: 10.1073/pnas.68.10.2325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. May P. R., Van Putten T. Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature. Arch Gen Psychiatry. 1978 Sep;35(9):1081–1087. doi: 10.1001/archpsyc.1978.01770330055004. [DOI] [PubMed] [Google Scholar]
  6. Phillipson O. T., McKeown J. M., Baker J., Healey A. F. Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis. Br J Psychiatry. 1977 Aug;131:172–184. doi: 10.1192/bjp.131.2.172. [DOI] [PubMed] [Google Scholar]
  7. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  8. Rivera-Calimlim L., Castañeda L., Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):978–986. doi: 10.1002/cpt1973146978. [DOI] [PubMed] [Google Scholar]
  9. Rivera-Calimlim L., Gift T., Nasrallah H. A., Wyatt R. J., Lasagna L. Correlation between plasma concentrations of chlorpromazine and clinical response. Commun Psychopharmacol. 1978;2(3):215–222. [PubMed] [Google Scholar]
  10. Rivera-Calimlim L., Nasrallah H., Strauss J., Lasagna L. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry. 1976 Jun;133(6):646–652. doi: 10.1176/ajp.133.6.646. [DOI] [PubMed] [Google Scholar]
  11. Sakalis G., Chan T. L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia. 1973 Sep 28;32(3):279–284. doi: 10.1007/BF00422150. [DOI] [PubMed] [Google Scholar]
  12. Sakalis G., Chan T. L., Sathananthan G., Schooler N., Goldberg S., Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Commun Psychopharmacol. 1977;1(2):157–166. [PubMed] [Google Scholar]
  13. Sakalis G., Curry S. H., Mould G. P., Lader M. H. Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):931–946. doi: 10.1002/cpt1972136931. [DOI] [PubMed] [Google Scholar]
  14. Sakurai Y., Nakahara T., Takahashi R. Prediction of response to chlorpromazine treatment in schizophrenics. Psychopharmacologia. 1975 Oct 31;44(2):195–203. doi: 10.1007/BF00421010. [DOI] [PubMed] [Google Scholar]
  15. Sakurai Y., Takahashi R., Nakahara T., Ikenaga H. Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch Gen Psychiatry. 1980 Sep;37(9):1057–1062. doi: 10.1001/archpsyc.1980.01780220095011. [DOI] [PubMed] [Google Scholar]
  16. Snyder S. H. Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry. 1981 Apr;138(4):460–464. doi: 10.1176/ajp.138.4.460. [DOI] [PubMed] [Google Scholar]
  17. Snyder S. H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976 Feb;133(2):197–202. doi: 10.1176/ajp.133.2.197. [DOI] [PubMed] [Google Scholar]
  18. Taylor P., Fleminger J. J. ECT for schizophrenia. Lancet. 1980 Jun 28;1(8183):1380–1382. doi: 10.1016/s0140-6736(80)92653-7. [DOI] [PubMed] [Google Scholar]
  19. Traficante L. J., Siekierski J., Sakalis G., Gershon S. Sulfoxidation of chlorpromazine and thioridazine by bovine liver--preferential metabolic pathways. Biochem Pharmacol. 1979 Mar 1;28(5):621–626. doi: 10.1016/0006-2952(79)90145-x. [DOI] [PubMed] [Google Scholar]
  20. Wode-Helgodt B., Alfredsson G. Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berl) 1981;73(1):55–62. doi: 10.1007/BF00431102. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES